Treatment with oxLDL antibody reduces cathepsin S expression in atherosclerosis via down-regulating ADAR1-mediated RNA editing

Int J Cardiol. 2017 Feb 15:229:7. doi: 10.1016/j.ijcard.2016.11.313. Epub 2016 Dec 6.

Authors

Jiehua Li¹, Zhaowei Zhu², Chang Shu³

Affiliations

¹ Department of Vascular Surgery, Second Xiangya Hospital of Central South University, Changsha, China.
² Department of Cardiology, Second Xiangya Hospital of Central South University, Changsha, China.
³ Department of Vascular Surgery, Second Xiangya Hospital of Central South University, Changsha, China. Electronic address: changshu01@yahoo.com.

PMID: 27956316
DOI: 10.1016/j.ijcard.2016.11.313

No abstract available

Keywords: ADAR1; Atherosclerosis; Cathepsin S; RNA editing; oxLDL.

Publication types

Letter

MeSH terms

Adenosine Deaminase / metabolism*
Antibodies, Monoclonal / pharmacology*
Cathepsins / metabolism*
Coronary Artery Disease* / metabolism
Coronary Artery Disease* / therapy
Down-Regulation
Humans
Immunologic Factors / pharmacology
Lipoproteins, LDL* / antagonists & inhibitors
Lipoproteins, LDL* / immunology
RNA Editing / drug effects
RNA-Binding Proteins / metabolism*
Recombinant Proteins / pharmacology

Substances

Antibodies, Monoclonal
Immunologic Factors
Lipoproteins, LDL
RNA-Binding Proteins
Recombinant Proteins
oxidized low density lipoprotein
Cathepsins
cathepsin S
ADAR protein, human
Adenosine Deaminase